Figure 1
Distinct roles for Hsp90α and Hsp90β in cancer cell survival and tumourigenicity. (A) Survival of MDA-MB-231 cells under drug selection following CRISPR-Cas9 Hsp90α gene (panels a, b and c) or Hsp90β gene (panels d, e and f) knockout was measured by counting the live cells over time (n=4). (B) Two Hsp90α-knockout clones (KO-α#1 and KO-α#2) showed complete absence of Hsp90α protein (panel g, lanes 3 and 4), in comparison with either short hairpin RNA (shRNA)-Hsp90α knockdown (lane 2) or the native MDA-MB-231 (lane 1) cells. (C) Specificity of the anti-Hsp90α and Hsp90β antibodies was confirmed by using the recombinant proteins in the Western. (D) Hsp90α gene knockout blocks Hsp90α (panel l), but not Hsp90β (panel m), secretion. (E) Growth curves of the native, shRNA-Hsp90α-knockdown (shRNA-α) and Hsp90α-knockout (KO-α-#1) MDA-MB-231 cells in the absence or presence of 10% foetal bovine serum (FBS). (F) Effect of Hsp90α gene on signalling in response to epidermal growth factor or TGFα.
